“An Efficacy and Safety Comparison of Regorafenib and Nivolumab in Unresectable Hepatocellular Cancer Patients: A Systematic Review”, ama, vol. 53, no. 1, pp. 46–58, Apr. 2024, doi: 10.5644/ama2006-124.443.